Navigation Links
Eprodisate in Medical News

Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational pr...

Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis

ECUBLENS, Switzerland, Dec. 14 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medi...

Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review

ECUBLENS, Switzerland, Dec. 6 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company has received an acknowledgement from the United States Food and Drug Administration (FDA) tha...

BELLUS Health reports results for first quarter of fiscal 2009

...revenue (non-monetary liability) to accrued liability (monetary liability) following the recovery by the Company of ownership rights in and control of eprodisate (KIACTA(TM)). Other income amounted to $529,000 for the current quarter, compared to $278,000 for the same quarter the previous year. Other incom...

BELLUS Health reports results for the fourth quarter of 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ision to continue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the US Food...

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update

...arily due to funds used in operating activities. eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis With respect to eprodisate (KIACTA(TM)), the Company submitted a proposed pro...II trial, should be sufficient to gain approval of eprodisate (KIACTA(TM)) for the treatment of AA Amyloidosis,....

BELLUS Health provides update on activities

...lic syndrome and Alzheimer's disease. The Company expects to file the Investigational New Drug application for the second Phase III clinical trial for eprodisate (KIACTA(TM)) for the treatment of Amyloid A amyloidosis in the fourth quarter of 2008. With respect to this second Phase III KIACTA(TM) clinical tri...

BELLUS HEALTH reports results for first quarter of fiscal 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ecision to pursue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Fo...

At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)

...also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of Johnson and ...ly announced, Neurochem will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administratio...

Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives

...n July 2007 for the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i... the marketing authorization application (MAA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i...ts of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns...
Eprodisate in Medical Technology

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. , announces that the New England Journal of Medicine (NEJM) published the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT), recognize...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

...t Neurochem Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by th...
Other Tags
(Date:8/1/2014)... Summer is here, and with it comes the season ... they can be a pain for dogs. Animal Emergency & ... customers get rid of ticks and prevent them completely. , ... summer, which is why they are so active during this ... areas and carry a number of diseases, including lyme disease, ...
(Date:8/1/2014)... August 01, 2014 As AndroGel lawsuits ... country, Ronald E. Johnson, Jr. has been appointed as ... and other testosterone medications. Since the Fall of 2013, ... have worked diligently to investigate and prosecute the claims ... and blood clots as a result of taking testosterone. ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
(Date:8/1/2014)... Hawley, PA (PRWEB) August 01, 2014 Hot ... in the destination spa category of the World’s Best ... kicks off a month-long celebration of National Relaxation Day (technically ... together a series of MAJOR experts to help guests celebrate ... how important it is for health and wellness to carve ...
Breaking Medicine News(10 mins):Health News:Tis the Season for Tick Prevention 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4
(Date:8/1/2014)... Scripps Research Institute (TSRI) have identified a signaling pathway ... fat cells. , The study, which is reported ... Proceedings of the National Academy of Sciences , sheds ... which is of great interest to medical researchers because ... against diabetes. , "This finding offers new possibilities for ...
(Date:7/31/2014)... from shale rock has increased by more than ... not fully understand the industry,s effects on nature ... journal Frontiers in Ecology and the Environment ... outpace scientific examination, a team of eight conservation ... University, concluded that determining the environmental impact of ...
(Date:7/31/2014)... Fla. --- By tracing nearly 3,000 genes to ... University of Florida scientists have created an extensive ... use large-scale, next-generation DNA sequencing. , Among ... closely related to small moths than to large ... butterflies evolved. The study also found that some ...
Breaking Biology News(10 mins):Scripps Research Institute scientists find new calorie-burning switch in brown fat 2Scripps Research Institute scientists find new calorie-burning switch in brown fat 3'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3
Other Contents